Long-Term Administration of Endothelin Receptor Antagonist Improves Coronary Endothelial Function in Patients With Early Atherosclerosis

被引:137
|
作者
Reriani, Martin [1 ]
Raichlin, Eugenia [1 ]
Prasad, Abhiram [1 ]
Mathew, Verghese [1 ]
Pumper, Geralyn M. [1 ]
Nelson, Rebecca E. [1 ]
Lennon, Ryan [1 ]
Rihal, Charanjit [1 ]
Lerman, Lilach O. [1 ]
Lerman, Amir [1 ]
机构
[1] Mayo Clin, Div Cardiovasc Dis, Rochester, MN 55905 USA
基金
美国国家卫生研究院;
关键词
blood flow; coronary disease; endothelin; endothelium; REFRACTORY PROSTATE-CANCER; NITRIC-OXIDE; EXPERIMENTAL HYPERCHOLESTEROLEMIA; ESSENTIAL-HYPERTENSION; ENDOGENOUS ENDOTHELIN; CONTROLLED-TRIAL; HUMAN ARTERIES; MESSENGER-RNA; FLOW VELOCITY; EX-VIVO;
D O I
10.1161/CIRCULATIONAHA.110.967406
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Endothelin (ET-1) is one of the most potent vasoconstrictors and plays a seminal role in the pathogenesis of atherosclerosis. The present study was designed to test the hypothesis that long-term treatment with an endothelin-A (ET(A)) receptor antagonist improves coronary endothelial function in patients with early coronary atherosclerosis. Methods and Results-Forty-seven patients with multiple cardiovascular risk factors, nonobstructive coronary artery disease, and coronary endothelial dysfunction were randomized in a double-blind manner to either the ET(A) receptor antagonist atrasentan (10 mg) or placebo for 6 months. Coronary endothelium-dependent vasodilation was examined by infusing acetylcholine (10(-6) to 10(-4) mol/L) in the left anterior descending coronary artery. N(G)-monomethyl-L-arginine was administered to a subgroup of patients. Endothelium-independent coronary flow reserve was examined by use of intracoronary adenosine and nitroglycerin. Baseline characteristics and incidence of adverse effects were similar between the 2 groups. There was a significant improvement in percent change of coronary blood flow in response to acetylcholine at 6 months from baseline in the atrasentan group compared with the placebo group (39.67%, 95% confidence interval 23.23% to 68.21%, versus -2.22%, 95% confidence interval -27.37% to 15.28%; P<0.001). No significant difference in the percent change of coronary artery diameter or change in coronary flow reserve was demonstrated. Coronary blood flow, coronary artery diameter, and the effect of N(G)-monomethyl-L-arginine were similar between the groups at baseline and at 6 months. Conclusions-This study demonstrates that 6-month treatment with atrasentan improves coronary microvascular endothelial function and supports the role of the endogenous endothelin system in the regulation of endothelial function in early atherosclerosis in humans.
引用
收藏
页码:958 / 966
页数:9
相关论文
共 50 条
  • [1] LONG TERM ENDOTHELIN RECEPTOR ANTAGONIST IMPROVES CORONARY ENDOTHELIAL FUNCTION IN PATIENTS WITH EARLY ATHEROSCLEROSIS
    Martin, Reriani Kaiga
    Raichlin, Eugenia
    Prasad, Abhiram
    Mathew, Verghese
    Lennon, Ryan
    Rihal, Charanjit
    Lerman, Lilach
    Lerman, Amir
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (10)
  • [2] Long-term endothelin receptor antagonism attenuates coronary plaque progression in patients with early atherosclerosis
    Yoon, Myeong Ho
    Reriani, Martin
    Mario, Goessl
    Rihal, Charanjit
    Gulati, Rajiv
    Lennon, Ryan
    Tilford, Jonella M.
    Lerman, Lilach O.
    Lerman, Amir
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 168 (02) : 1316 - 1321
  • [3] Long-term endothelin receptor blockade improves cardiovascular function in diabetes
    Verma, S
    Arikawa, E
    McNeill, JH
    AMERICAN JOURNAL OF HYPERTENSION, 2001, 14 (07) : 679 - 687
  • [4] Long term endothelial receptor antagonism attenuates coronary plaque progression in patients with early atherosclerosis
    Reriani, M.
    Ho, Y. Myeong
    Gossl, M.
    Rihal, C.
    Tilford, J.
    Flammer, A.
    Lerman, L.
    Lerman, A.
    EUROPEAN HEART JOURNAL, 2011, 32 : 256 - 256
  • [5] Long-term treatment with probucol improves endothelial function in patients with coronary artery disease
    Tagawa, T
    Urabe, Y
    Kimura, Y
    Suzuki, S
    Ono, H
    Takeda, K
    HYPERTENSION RESEARCH, 2004, 27 (05) : 311 - 318
  • [6] Short-term improvement of coronary endothelial function improves long-term prognosis in early stages of coronary disease
    Baller, D.
    Gleichmann, U.
    Holzinger, J.
    Bitter, T.
    Horstkotte, D.
    CARDIOVASCULAR RESEARCH, 2010, 87 : S82 - S82
  • [7] Intracoronary endothelin receptor blockade improves endothelial function in patients with coronary artery disease
    Bohm, Felix
    Jensen, Jens
    Svane, Bertil
    Settergren, Magnus
    Pernow, John
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2008, 86 (11) : 745 - 751
  • [8] The TP receptor antagonist S 18886 improves endothelial dysfunction on a long-term basis in atherosclerotic patients
    Belhassen, L
    EUROPEAN HEART JOURNAL, 2004, 25 : 97 - 97
  • [9] Long-term endothelin receptor antagonist administration improves alterations in expression of various cardiac genes in failing myocardium of rats with heart failure
    Sakai, S
    Miyauchi, T
    Yamaguchi, I
    CIRCULATION, 2000, 101 (24) : 2849 - 2853
  • [10] Long-term, regular remote ischemic preconditioning improves endothelial function in patients with coronary heart disease
    Liang, Y.
    Li, Y. P.
    He, F.
    Liu, X. Q.
    Zhang, J. Y.
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2015, 48 (06) : 568 - 576